Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells

Molecular Pharmacology

Volumn 63, Issue 3, 2003, Pages 632-638

  Biroccio, Annamaria ^a   Gabellini, Chiara ^a   Amodei, Sarah ^a   Benassi, Barbara ^a   Del Bufalo, Donatella ^a   Elli, Raffaella ^b   Antonelli, Anna ^b   D'Incalci, Maurizio ^c   Zupi, Gabriella ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DNA; LONIDAMINE; RNA DIRECTED DNA POLYMERASE; TELOMERASE; TRABECTEDIN;

APOPTOSIS; ARTICLE; CELL CYCLE G2 PHASE; CELL SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MELANOMA CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TELOMERE;

ANTINEOPLASTIC AGENTS; CISPLATIN; DIOXOLES; DNA DAMAGE; DNA-BINDING PROTEINS; DRUG SCREENING ASSAYS, ANTITUMOR; G2 PHASE; HUMANS; ISOQUINOLINES; MELANOMA; MITOSIS; TELOMERASE; TELOMERE; TETRAHYDROISOQUINOLINES; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0037333478     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.63.3.632     Document Type: Article

References (30)

1. Bearss DJ, Hurley LH, and Von Hoff DD (2000) Telomere maintenance mechanisms as a target for drug development. Oncogene 19:6632-6641.
2. Biroccio A, Amodei S, Benassi B, Scarsella M, Cianciulli A, Mottolese M, Del Bufalo D, Leonetti C, and Zupi G (2002) Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones. Oncogene 21:3011-3019.
3. Biroccio A, Benassi B, Amodei S, Gabellini C, Del Bufalo D, and Zupi G (2001) c-Myc down-regulation increases susceptibility to cisplatin through reactive oxygen species-mediated apoptosis in M14 human melanoma cells. Mol Pharmacol 60:174-182.
4. Citro G, Cucco C, Verdina A, and Zupi G (1991) Reversal of ADR resistance by lonidamine in a human breast cancer cell lines. Br J Cancer 64:534-536.
5. Damia G, Imperatori L, Stefanini M, and D'Incalci M (1996) Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents. Int J Cancer 66:779-783.
6. Del Bufalo D, Biroccio A, Soddu S, Laudonio N, D'Angelo C, Sacchi A, and Zupi G (1996) Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. J Clin Investig 98:1165-1173.
7. D'Incalci M, Erba E, Damia G, Tiozzo G, Ubezio P, Meco D, Riccardi R, Nicoletti I, Gavazzi R, Carcassa L, et al. (2002) The combination of ET-743 and cisplatin (DDP): from a molecular pharmacology study to a Phase I clinical trial (Abstract). Am Assoc Cancer Res 43:80.
8. Erba E, Bergamaschi D, Bassano L, Damia G, Rozoni S, Faircloth GT, and D'Incalci M (2001) Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 37:97-105.
9. Folini M, De Marco C, Orlandi L, Daidone MG, and Zaffaroni N (2000) Attenuation of telomerase activity does not increase sensitivity of human melanoma cells to anticancer agents. Eur J Cancer 36:2137-2145.
10. Fu W, Begley JG, Killen MW, and Mattson MP (1999) Anti-apoptotic role of telomerase in pheochromocytoma cells. J Biol Chem 274:7264-7271.
11. Gajate C, An F, and Mollinedo F(2002) Differential cytostatic and apoptotic effects of ecteinascidin-743 in cancer cells. Transcription-dependent cell cycle arrest and transcription-independent JNK and mitochondrial mediated apoptosis. J Biol Chem 277:41580-41589.
12. Guiducci C, Cerone MA, and Bacchetti S (2001) Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability. Oncogene 20:714-725.
13. Izbicka E, Lawrence R, Raymond E, Eckhardt G, Faircloth G, Jimeno J, Clark G, and Von Hoff DD (1998) In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann Oncol 9:981-987.
14. Jin S, Gorfajn B, Faircloth G, and Scotto KW (2000) Ecteinascidin-743, a transcription-targeted chemotherapeutic that inhibits MDR1 activation. Proc Natl Acad Sci USA 97:6775-6779.
15. Kelland LR (2001) Telomerase: biology and phase I trials. Lancet Oncol 2:95-102.
16. Kondo Y, Kondo S, Tanaka Y, Haqqi T, Barna BP, and Cowell JK (1998) Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis. Oncogene 16:2243-2248.
17. Lee KH, Rudolph KL, Ju YJ, Greenberg RA, Cannizzaro L, Chin L, Weiler SR, and DePinho RA (2001) Telomere dysfunction alters the chemotherapeutic profile of transformed cells. Proc Acad Sci USA 98:3381-3386.
18. Ludwig A, Saretzki G, Holm PS, Tiemann F, Lorenz M, Emrich T, Harley CB, and von Zglinicki T (2001) Ribozyme cleavage of telomerase mRNA sensitizes breast epithelial cells to inhibitors of topoisomerase. Cancer Res 61:3053-3061.
19. Minuzzo M, Marchini S, Broggini M, Faircloth G, D'Incalci M, and Mantovani R (2000) Interference of transcriptional activation by the anti-neoplastic drug ecteinascidin-743. Proc Natl Acad Sci USA 97:6780-6784.
20. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, and Kohn KW (1996) DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 35:13303-13309.
21. Shay JW and Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791.
22. Shen M, Haggblom C, Vogt M, Hunter T, and Lu KP (1997) Characterization and cell cycle regulation of the related human telomeric proteins Pin2 and TRF1 suggest a role in mitosis. Proc Natl Acad Sci USA 94:13618-13623.
23. Silvestrini R, Zaffaroni N, Villa R, Ordandi L, and Costa A (1992) Enhancement of cisplatin activity by LND in human ovarian cancer cells. Int J Cancer 52:813-817.
24. Sorenson CM and Eastman A (1988) Influence of cis-diamminedichloroplatinum(II) on DNA synthesis and cell cycle progression in excision repair proficient and deficient Chinese hamster ovary cells. Cancer Res 48:6703-6707.
25. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagan G, and Pommier Y (2001a) Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res 7:185-191.
26. Takebayashi Y, Pourquier P, Zimonjic DB, Nakayama K, Emmert S, Ueda T, Urasaki Y, Kanzaki A, Akiyama SI, Popescu N, et al. (2001b) Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med 7:961-966.
27. Valoti G, Nicoletti MI, Pellegrino A, Jimeno J, Hendrisk H, D'Incalci M, Faircloth G, and Giavazzi R (1998) Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. Clin Cancer Res 4:1977-1983.
28. Villalona-Calero MA, Eckhardt SG, Weiss G, Hidalgo M, Beijnen JH, van Kesteren C, Rosing H, Campbell E, Kraynak M, Lopez-Lazaro L, et al. (2002) A phase I and pharmacokinetic study of ecteinascidin-743 on a daily × 5 schedule in patients with solid malignancies. Clin Cancer Res 8:75-85.
29. Wong KK, Chang S, Weiler SR, Ganesan S, Chaudhuri J, Zhu C, Artandi SE, Rudholph KL, Gottlieb GJ, Chin L, et al. (2000) Telomere dysfunction impairs DNA repair and enhances sensitivity to ionizing radiation. Nat Genet 26:85-88.
30. Zhou XZ and Lu KP (2001) The Pin2/TRFl-interacting protein PinX1 is a potent telomerase inhibitor. Cell 2:347-359.